Algert Global LLC Invests $1.22 Million in GoodRx Holdings, Inc. $GDRX

Key Points

• Algert Global LLC purchased 277,650 shares of GoodRx Holdings, valued at approximately $1,224,000, marking a new position in the company as of the 1st quarter.
• Several institutional investors significantly increased their stakes in GoodRx Holdings, with Jacobs Levy Equity Management growing its position by 303.3% during the fourth quarter.
• GoodRx reported earnings of $0.09 per share for the latest quarter, missing analysts' estimates, with revenue slightly down year-over-year at $203.07 million, compared to an expected $205.72 million.

Algert Global LLC bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 277,650 shares of the company's stock, valued at approximately $1,224,000. Algert Global LLC owned 0.07% of GoodRx at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of GDRX. Geode Capital Management LLC boosted its stake in GoodRx by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after acquiring an additional 89,032 shares in the last quarter. Barclays PLC increased its stake in shares of GoodRx by 18.4% during the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after purchasing an additional 25,815 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of GoodRx by 13.5% during the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after purchasing an additional 50,256 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of GoodRx in the 1st quarter worth approximately $315,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of GoodRx in the 4th quarter worth approximately $314,000. 63.77% of the stock is currently owned by institutional investors.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.53% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GDRX shares. UBS Group reduced their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, The Goldman Sachs Group cut their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, GoodRx presently has an average rating of "Hold" and an average price target of $5.80.

GoodRx Stock Performance

GDRX traded down $0.11 during mid-day trading on Thursday, reaching $4.40. 315,279 shares of the company traded hands, compared to its average volume of 1,990,017. The company's fifty day moving average price is $4.58 and its 200-day moving average price is $4.50. The stock has a market capitalization of $1.53 billion, a P/E ratio of 43.95, a P/E/G ratio of 1.89 and a beta of 1.24. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx Holdings, Inc. has a 52-week low of $3.31 and a 52-week high of $8.38.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The firm had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same period in the previous year, the firm earned $0.08 EPS. The business's revenue was up 1.2% on a year-over-year basis. On average, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.